Motus GI Holdings, Inc. (MOTS)
| Previous close | 0.0694 |
| Open | 0.0522 |
| Bid | 0.0480 x 0 |
| Ask | 0.0586 x 0 |
| Day's range | 0.0460 - 0.0600 |
| 52-week range | 0.0460 - 11.2500 |
| Volume | |
| Avg. volume | 216,061 |
| Market cap | 265,368 |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holding
- GlobeNewswire
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FO
- GlobeNewswire
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock for gross proceeds to the Comp
